From the Food and Drug Administration.
Henney
J E
JE
Commissioner of Food and Drugs, Rockville, MD 20857, USA.
D000284:Administration, Oral; D000998:Antiviral Agents / Q000009:adverse effects*; D016572:Cyclosporine / Q000008:administration & dosage*; D004348:Drug Labeling; D004335:Drug and Narcotic Control; D005473:Fluoxetine / Q000627:therapeutic use*; D006146:Guanidines; D006266:Health Education; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D020407:Internet; D009369:Neoplasms; D011293:Premenstrual Syndrome / Q000188:drug therapy*; D011714:Pyrans; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012794:Sialic Acids / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D053243:Zanamivir
D000998:Antiviral Agents; D016572:Cyclosporine; D005473:Fluoxetine; D006146:Guanidines; D007166:Immunosuppressive Agents; D011714:Pyrans; D017367:Selective Serotonin Reuptake Inhibitors; D012794:Sialic Acids; D053243:Zanamivir